We can’t show the full text here under this license. Use the link below to read it at the source.
Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12‐month data from the OpT2mise randomized trial
Long-term benefits of insulin pump therapy versus multiple daily injections in type 2 diabetes over 12 months
AI simplified
Abstract
At the end of a 6-month randomized phase, pump therapy led to a significantly greater reduction in HbA1c compared to multiple daily injections (MDI).
- The mean HbA1c reduction with pump therapy was -1.1 ± 1.2%, compared to -0.4 ± 1.1% for MDI.
- After switching from MDI to pump therapy, the HbA1c reduction in the MDI-pump group was 0.8%, resulting in identical final HbA1c levels in both groups.
- Total daily insulin dose was 20.4% lower with pump therapy during the randomized phase and remained stable in the continuation phase.
- By 12 months, total daily insulin doses were equivalent in both groups.
- No differences in weight gain or ketoacidosis were observed between the two treatment groups.
AI simplified
Key numbers
-1.1 ± 1.2%
HbA1c Reduction
Comparison of HbA1c change at 6 months between pump therapy and MDI.
20.4%
Total Daily Insulin Dose Reduction
Difference in total daily insulin dose during the randomization phase.
7.8%
Final HbA1c Level
Final HbA1c level at 12 months for both pump and MDI groups.